One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Pfizer is advancing research and building a comprehensive "toolbox" for Vietnamese patients, combining innovative vaccines, ...

On World Humanitarian Day, Pfizer Canada is proud to mark 30 years of partnership with Health Partners International of Canada (HPIC), a collaboration that has delivered over $70 million worth of life ...

The U.S. stock market ended Monday’s session nearly flat as traders awaited the retail earnings deluge and some key economic ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.